Effects of angiotensin II receptor antagonist on impaired endothelium-dependent and endothelium-independent relaxations in type II diabetic rats

Journal of Hypertension
Hideyuki OnikiMitsuo Iida

Abstract

Diabetes mellitus is an important risk factor for cardiovascular diseases, and vasodilator dysfunction may contribute to vascular complications in diabetes. We previously demonstrated that the angiotensin II receptor blocker (ARB) corrected the impaired endothelium-derived hyperpolarizing factor (EDHF)-mediated arterial hyperpolarization and relaxation associated with hypertension or aging, partially independently of blood pressure. To test whether EDHF-mediated, as well as endothelium-independent, relaxations would be altered in arteries from type II diabetic Goto-Kakizaki rats, and whether ARB would correct these alterations. Goto-Kakizaki rats were treated with either the ARB candesartan or a combination of hydralazine and hydrochlorothiazide for 8 weeks, beginning at 10 weeks of age. Membrane potentials and contractile responses were recorded from the isolated mesenteric arteries. The two treatments lowered blood pressure comparably. Acetylcholine-induced, EDHF-mediated hyperpolarization and relaxation in mesenteric arteries were markedly impaired in untreated Goto-Kakizaki rats compared with age-matched Wistar rats, and neither ARB nor the combination therapy improved these responses. On the other hand, relaxations to endo...Continue Reading

References

May 1, 1976·The Tohoku Journal of Experimental Medicine·Y GotoN Masaki
Mar 1, 1988·British Journal of Pharmacology·M Feletou, P M Vanhoutte
Dec 1, 1995·Circulation·R A Cohen, P M Vanhoutte
Dec 24, 1997·European Heart Journal·P M Vanhoutte
Jul 6, 2000·British Journal of Pharmacology·A S De VrieseP M Vanhoutte
Dec 20, 2000·The Journal of Clinical Investigation·T MatobaA Takeshita
Feb 7, 2001·Circulation Research·U HinkT Munzel
Mar 5, 2002·Journal of Hypertension·Yasuo KansuiMitsuo Iida
Jun 13, 2002·Clinical and Experimental Pharmacology & Physiology·Kenichi GotoMitsuo Iida
Oct 16, 2002·Trends in Pharmacological Sciences·Rudi BusseArthur H Weston
Apr 26, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Norman Nor ChanHelen Martina Colhoun
Dec 6, 2003·Stroke; a Journal of Cerebral Circulation·Carol A GunnettFrank M Faraci
Mar 22, 2005·European Journal of Pharmacology·Milad S BitarFahd Al-Mulla

❮ Previous
Next ❯

Citations

Oct 2, 2009·Clinical and Experimental Pharmacology & Physiology·Mitsuo MitaMasaru Shoji
Feb 3, 2011·World Journal of Cardiology·Xue GaoCuihua Zhang
May 7, 2008·European Journal of Pharmacology·Gen MatsuzakiRyozo Nagai
Oct 7, 2010·Journal of Diabetes·Yi Shi, Paul Michel Vanhoutte
Aug 3, 2019·International Journal of Molecular Sciences·Kenichi Goto, Takanari Kitazono

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.